BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OPX Biotechnologies Wins $6 Million Department of Energy Grant


4/30/2010 9:48:55 AM

WASHINGTON, DC and BOULDER, CO--(Marketwire - April 30, 2010) - OPX Biotechnologies Inc. (OPXBIO), a renewable biochemical and biofuel company, has been awarded a $6 million grant for the development of advancement biofuels by the U.S. Department of Energy through its Advanced Research Project Agency - Energy (ARPA-E). OPXBIO is one of 37 institutions selected by the DOE from among 540 applicants to receive an ARPA-E grant in this round of funding. Vice President Joe Biden and Secretary of Energy Steven Chu announced the award winners yesterday at a meeting of the Recovery Act Cabinet in Washington DC.

"OPXBIO is pleased and honored to receive this recognition and grant from the Department of Energy through its ARPA-E agency," said Charles (Chas) Eggert, OPXBIO President and CEO. "We are eager to apply these funds, along with capital from our private investors, to accelerate development of advanced, renewable biofuels. Together with our project partners, the National Renewable Energy Laboratory in Golden, CO and Johnson Matthey Catalysts LLC, we will develop a new, economical bioprocess to convert hydrogen and carbon dioxide into diesel and jet fuel products that can compete to replace petroleum derived products without the need for price subsidies."

The ARPA-E funding award to OPXBIO provides additional validation of the company's proprietary EDGE™ (Efficiency Directed Genome Engineering) technology platform, which enables rapid development of economical and sustainable bioprocesses for the production of chemicals and fuels from a variety of renewable raw materials.

In this second round of ARPA-E funding, the U.S. Department of Energy awarded $106 million for research projects that could fundamentally change the way the country uses and produces energy. The funds were awarded to projects that could produce advanced biofuels more efficiently from renewable electricity instead of sunlight; design completely new types of batteries to make electric vehicles more affordable; and remove the carbon pollution from coal-fired power plants in a more cost-effective way.

Commenting on the awards, Secretary Chu said, "These projects show that the U.S. can lead the next Industrial Revolution in clean energy technologies, which will help create new jobs, spur innovation and economic growth while helping to cut carbon pollution dramatically."

About OPXBIO
OPXBIO is a Colorado-based company using biotechnology to convert renewable raw materials into biochemicals and biofuels. Applying its EDGE™ (Efficiency Directed Genome Engineering) technology, OPXBIO will manufacture bio-based products that are more economical and sustainable than petroleum-based alternatives. OPXBIO has already demonstrated laboratory-scale production of several different biochemicals and biofuels using renewable biomass as well as carbon dioxide and hydrogen feedstock. The company currently is producing bioacrylic at pilot scale in advance of opening a demonstration plant in 2011 and a full-scale commercial plant in 2013. The company also is developing strategic partnerships and joint ventures for commercialization.

OPXBIO has also raised $22.4 million with venture investors Mohr Davidow Ventures, Braemar Energy Ventures, Altira Group, and X/Seed Capital.

For more information, visit http://www.opxbiotechnologies.com.


Media Contact:
Lisa Hempel
Cohn Marketing
303.839.1415 ext. 52
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES